RedHill Biopharma Ltd. Expected to Post FY2018 Earnings of ($2.00) Per Share (RDHL)
RedHill Biopharma Ltd. (NASDAQ:RDHL) – Research analysts at Roth Capital dropped their FY2018 EPS estimates for RedHill Biopharma in a research note issued to investors on Monday. Roth Capital analyst S. Henry now anticipates that the firm will post earnings of ($2.00) per share for the year, down from their prior forecast of ($1.60).
RedHill Biopharma (NASDAQ:RDHL) last issued its quarterly earnings data on Wednesday, July 27th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.52.
Several other research firms have also recently issued reports on RDHL. FBR & Co reissued an “outperform” rating and issued a $36.00 target price on shares of RedHill Biopharma in a research note on Wednesday. Zacks Investment Research raised RedHill Biopharma from a “hold” rating to a “buy” rating and set a $11.00 target price on the stock in a research note on Tuesday, June 28th. Finally, HC Wainwright set a $33.00 target price on RedHill Biopharma and gave the stock a “buy” rating in a research note on Friday, October 7th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $26.20.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/12/redhill-biopharma-ltd-expected-to-post-fy2018-earnings-of-2-00-per-share-rdhl.html
Shares of RedHill Biopharma (NASDAQ:RDHL) traded up 1.7170% during mid-day trading on Wednesday, hitting $14.2709. The stock had a trading volume of 13,925 shares. The stock’s 50-day moving average price is $14.63 and its 200-day moving average price is $12.81. The firm’s market cap is $181.73 million. RedHill Biopharma has a 52-week low of $8.10 and a 52-week high of $16.54.
Hedge funds have recently bought and sold shares of the stock. Royal Bank of Canada boosted its stake in RedHill Biopharma by 0.9% in the first quarter. Royal Bank of Canada now owns 21,167 shares of the company’s stock valued at $259,000 after buying an additional 191 shares during the last quarter. Oppenheimer & Co. Inc. purchased a new stake in RedHill Biopharma during the second quarter valued at $142,000. Ingalls & Snyder LLC purchased a new stake in RedHill Biopharma during the second quarter valued at $451,000. Finally, Van ECK Associates Corp boosted its stake in RedHill Biopharma by 1.5% in the second quarter. Van ECK Associates Corp now owns 9,623 shares of the company’s stock valued at $105,000 after buying an additional 138 shares during the last quarter. 15.30% of the stock is currently owned by institutional investors and hedge funds.
About RedHill Biopharma
Receive News & Ratings for RedHill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.